新股消息 | 百力司康拟港股上市 中国证监会要求补充说明公司经营管理的实际运作等情况

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for BlissBio Inc. as part of its overseas listing application process, highlighting the need for detailed explanations regarding the company's management operations and financial transactions [1][2]. Group 1: Regulatory Requirements - The CSRC has requested BlissBio Inc. to provide clarifications on several financial and operational aspects, including the pricing basis for the acquisition of CCCBio and tax implications for the involved parties [1]. - Specific inquiries include the tax situation related to the capital reduction process in Hangzhou, the relationship between shareholders, and compliance with foreign exchange management regulations [1][2]. - The CSRC also seeks to understand the reasons behind the lack of simultaneous capital reduction for the Shenyang entity and the implications of the acquisition of equity in Hangzhou [1][2]. Group 2: Company Overview - BlissBio Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address unmet needs in cancer treatment [2]. - The company's lead product, BB-1701, targets the human epidermal growth factor receptor 2 (HER2) and is primarily aimed at treating breast cancer, non-small cell lung cancer, and other HER2-expressing cancers [2]. Group 3: Financial Performance - For the fiscal years 2023 and 2024, BlissBio Inc. reported revenues of approximately 180 million RMB and 22.591 million RMB, respectively, while incurring losses of about 206 million RMB and 55.7 million RMB during the same periods [3].